Herein, our aim was to evaluate HSP70/HSF1 axis involvement in ibrutinib-resistance in CLL and the effect of the inhibition of this axis as a strategy to bypass ibrutinib-resistance. This evidence concerns the gene HSF1 and B-cell chronic lymphocytic leukemia.